Seer and NTU Unveil Early Findings from Large-Scale Proteomics Study…

Event summary

Seer and Nanyang Technological University will present early findings from the PRECISE-SG100K study at the HUPO 2026 World Congress, September 27–October 1.
The study integrates proteomic data with genomic, clinical, and phenotypic information from 100,000 participants in Singapore's multi-ethnic population.
Seer's Proteograph® Product Suite is used for deep, unbiased mass spectrometry-based profiling in 10,000 participants.
The study aims to uncover biological signals and accelerate biomarker discovery for precision medicine.

The big picture

The PRECISE-SG100K study represents a significant advancement in population-scale proteomics, combining deep molecular characterization with diverse, multi-ethnic data. This approach could set a new standard for understanding health and disease at a granular level, potentially transforming precision medicine. The integration of Seer's Proteograph technology with high-performance mass spectrometry highlights the growing importance of proteomics in the AI-driven biology era.

What we're watching

Data Integration: How Seer and NTU will leverage the combined proteomic, genomic, and clinical data to drive actionable insights.
Technical Reproducibility: Whether the Proteograph workflow can maintain consistency and reproducibility across the large-scale study.
Biomarker Discovery: The pace at which the study will identify novel biomarkers and their potential impact on precision medicine.